Literature DB >> 23503837

Oral choline tolerance test as a novel noninvasive method for predicting nonalcoholic steatohepatitis.

Kento Imajo1, Masato Yoneda, Koji Fujita, Takaomi Kessoku, Wataru Tomeno, Yuji Ogawa, Yoshiyasu Shinohara, Yusuke Sekino, Hironori Mawatari, Yuichi Nozaki, Hiroyuki Kirikoshi, Masataka Taguri, Gen Toshima, Junichiro Takahashi, Satoru Saito, Koichiro Wada, Atsushi Nakajima.   

Abstract

BACKGROUND: Although therapeutic intervention for nonalcoholic steatohepatitis (NASH) at an early stage is important owing to the progressive nature of the disease, diagnosis using noninvasive methods remains difficult. We previously demonstrated NASH specific impairment of choline metabolism and the use of fasting plasma free choline (fCh) levels for NASH diagnosis. Here, we investigated the utility of an oral choline tolerance test (OCTT), based on disordered choline metabolism, as a novel noninvasive method for NASH diagnosis.
METHODS: Sixty-five patients with biopsy proven nonalcoholic fatty liver disease (NAFLD) and 17 healthy controls were enrolled. Blood samples were obtained from all subjects five times during the OCTT (before and 1, 2, 3, and 4 h after oral loading with 260 mg choline).
RESULTS: Four-hour fCh levels after oral loading choline were markedly increased in NASH patients, compared with non-NASH subjects. For detecting NASH, compared with non-NASH subjects, the area under the curve for 4-h fCh levels was 0.829 on receiver operating characteristic (ROC) analysis. The cut-off level for NASH diagnosis was ≥0.16 mg/dL, and the sensitivity, specificity, positive predictive value, and negative predictive value were 80.1, 82.6, 78.4, and 84.4 %, respectively. Moreover, 4-h fCh levels were significantly associated with the disease activity based on NAFLD activity score in patients with NAFLD.
CONCLUSIONS: Four-hour fCh levels obtained by an OCTT reflect a NASH specific disorder of choline metabolism, suggesting that the OCTT is a novel and useful noninvasive method for diagnosing NASH at an early stage with sufficient accuracy for clinical practice.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23503837     DOI: 10.1007/s00535-013-0776-3

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  33 in total

1.  High sensitivity C-reactive protein values do not reliably predict the severity of histological changes in NAFLD.

Authors:  Jason M Hui; Geoffrey C Farrell; James G Kench; Jacob George
Journal:  Hepatology       Date:  2004-05       Impact factor: 17.425

2.  Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease.

Authors:  Hiroyuki Kaneda; Etsuko Hashimoto; Satoru Yatsuji; Katsutoshi Tokushige; Keiko Shiratori
Journal:  J Gastroenterol Hepatol       Date:  2006-09       Impact factor: 4.029

3.  Breath biomarkers and non-alcoholic fatty liver disease: preliminary observations.

Authors:  S F Solga; A Alkhuraishe; K Cope; A Tabesh; J M Clark; M Torbenson; P Schwartz; T Magnuson; A M Diehl; T H Risby
Journal:  Biomarkers       Date:  2006 Mar-Apr       Impact factor: 2.658

4.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

5.  Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C.

Authors:  Jason M Hui; James G Kench; Shivakumar Chitturi; Archana Sud; Geoffrey C Farrell; Karen Byth; Pauline Hall; Mahbub Khan; Jacob George
Journal:  Hepatology       Date:  2003-08       Impact factor: 17.425

6.  Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers.

Authors:  Indra Neil Guha; Julie Parkes; Paul Roderick; Dipanker Chattopadhyay; Richard Cross; Scott Harris; Philip Kaye; Alastair D Burt; Steve D Ryder; Guruprasad P Aithal; Christopher P Day; William M Rosenberg
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

Review 7.  Choline and human nutrition.

Authors:  S H Zeisel; J K Blusztajn
Journal:  Annu Rev Nutr       Date:  1994       Impact factor: 11.848

8.  Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations.

Authors:  Z M Younossi; T Gramlich; Y C Liu; C Matteoni; M Petrelli; J Goldblum; L Rybicki; A J McCullough
Journal:  Mod Pathol       Date:  1998-06       Impact factor: 7.842

9.  Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study.

Authors:  Ariel E Feldstein; Anna Wieckowska; A Rocio Lopez; Yao-Chang Liu; Nizar N Zein; Arthur J McCullough
Journal:  Hepatology       Date:  2009-10       Impact factor: 17.425

10.  Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH).

Authors:  Masato Yoneda; Takashi Uchiyama; Shingo Kato; Hiroki Endo; Koji Fujita; Kyoko Yoneda; Hironori Mawatari; Hiroshi Iida; Hirokazu Takahashi; Hiroyuki Kirikoshi; Masahiko Inamori; Yuichi Nozaki; Noritoshi Kobayashi; Kensuke Kubota; Satoru Saito; Shiro Maeyama; Mina Sagara; Hiroyuki Aburatani; Tatsuhiko Kodama; Atsushi Nakajima
Journal:  BMC Gastroenterol       Date:  2008-11-14       Impact factor: 3.067

View more
  3 in total

1.  Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis.

Authors:  B C Ferslew; C K Johnston; E Tsakalozou; A S Bridges; M F Paine; W Jia; P W Stewart; A S Barritt; K L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2015-03-15       Impact factor: 6.875

Review 2.  Nonalcoholic fatty liver disease in Asia: emerging perspectives.

Authors:  Wai-Kay Seto; Man-Fung Yuen
Journal:  J Gastroenterol       Date:  2016-09-16       Impact factor: 7.527

3.  LDL-migration index (LDL-MI), an indicator of small dense low-density lipoprotein (sdLDL), is higher in non-alcoholic steatohepatitis than in non-alcoholic fatty liver: a multicenter cross-sectional study.

Authors:  Kento Imajo; Hideyuki Hyogo; Masato Yoneda; Yasushi Honda; Takaomi Kessoku; Wataru Tomeno; Yuji Ogawa; Masataka Taguri; Hironori Mawatari; Yuichi Nozaki; Koji Fujita; Hiroyuki Kirikoshi; Satoru Saito; Yoshio Sumida; Masafumi Ono; Koichiro Wada; Atsushi Nakajima; Yuichiro Eguchi
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.